Hillstar Bio, Inc.

Hillstar Bio is a biopharmaceutical company focused on developing innovative treatments to address unmet medical needs in various therapeutic areas using advanced biotechnological processes. Founded in 2023 in Boston, US, Hillstar Bio specializes in creating biopharmaceutical products. In September 2023, Hillstar Bio raised USD 27. 93 million in series A funding co led by new investors Novo Holdings, LifeArc, Hummingbird Bioscience Holdings Pte.

Ltd. , Frazier Healthcare Partners, Droia Ventures.. Hillstar Bio specializes in the development of innovative biopharmaceutical products aimed at addressing significant unmet medical needs. The company's core offerings focus on therapeutic solutions designed to improve patient outcomes in various therapeutic areas.

These products involve advanced biotechnological processes, harnessing the power of biologics to create treatments that enhance the efficacy and safety of existing therapies. Hillstar Bio serves a diverse clientele, including healthcare providers, hospitals, and research institutions, primarily within the North American and European markets. The revenue structure of Hillstar Bio is primarily derived from partnerships and collaborations with healthcare institutions and pharmaceutical companies. Transactions typically occur through a B2B model, where the company offers subscription-based access to its proprietary therapies, along with research and development services.

Hillstar Bio's flagship products are offered through a direct sales approach, ensuring that healthcare providers have immediate access to their innovative solutions. The pricing structure reflects the value of the advanced biopharmaceutical technologies provided, supporting both the initial sale and ongoing access for clients, establishing recurring revenue streams and ensuring a steady market presence. In September 2023, Hillstar Bio raised USD 27. 93 million in series A funding co led by new investors Novo Holdings, LifeArc, Hummingbird Bioscience Holdings Pte.

Ltd. , Frazier Healthcare Partners, Droia Ventures, which will be utilized to advance its lead TRBV9 program through clinical trials for axial spondyloarthritis and to expand its pipeline of precision immunology therapies targeting autoimmune diseases. The company is also planning to explore new geographic markets in Europe and North America by late 2026, aiming to broaden the reach of its innovative therapeutic solutions.